Page 5 - Hepalys Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hepalys pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hepalys Pharma Today - Breaking & Trending Today

Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea -September 20, 2023 at 04:01 pm EDT

Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million. ....

United States , New York , San Francisco , South Korea , South Koreans , South Korean , Aude Lepreux , Catalys Pacific , Nonliver Comorbidities , Hepalys Pharma , Pascaline Clerc , Hepalys Pharma Inc , Global External Affairs , Exchange Commission On , Brunswick Group , Mitsubishi Ufj , Innovation Fund , Patricial Bank , Hepalys Pharma Inc We , Long Island City , Euronext Paris , Greater China , Representative Director , Breakthrough Therapy , Fast Track , Nasdaq Global Market ,

Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea - Inventiva (OTC:IVEVF), Inventiva (NASDAQ:IVA)

Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million upfront payment, and is ....

New York , United States , San Francisco , South Korea , South Koreans , South Korean , Hepalys Pharma , Nonliver Comorbidities , Catalys Pacific , Innovation Fund , Hepalys Pharma Inc We , Mitsubishi Ufj , Exchange Commission On , Hepalys Pharma Inc , Long Island City , Greater China , Representative Director , Breakthrough Therapy , Fast Track , Euronext Paris , Nasdaq Global Market , Private Securities Litigation Reform Act , New Drug Application , Universal Registration Document , Des March , Annual Report ,